Probiotics

American Journal of Health-System Pharmacy

Volumn 67, Issue 6, 2010, Pages 449-458

  Williams, Nancy Toedter ^a  

^a SOUTHWESTERN OKLAHOMA STATE UNIVERSITY   (United States)

Author keywords

Antiinfective agents; Contrain dications; Diarrhea; Dietary supplements; Dosage; Drug interactions; Mechanism of action; Probiotics; Regulations; Toxicity

Indexed keywords

ACTIVIA; MESALAZINE; METRONIDAZOLE; PLACEBO; PROBIOTIC AGENT; UNCLASSIFIED DRUG; VANCOMYCIN; VSL3;

ACUTE DIARRHEA; ANTIBIOTIC ASSOCIATED DIARRHEA; ATOPIC DERMATITIS; BACILLUS CEREUS; BACTEREMIA; BACTERIAL COLONIZATION; BIFIDOBACTERIUM; BIFIDOBACTERIUM ADOLESCENTIS; BIFIDOBACTERIUM ANIMALIS; BIFIDOBACTERIUM BIFIDUM; BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM LONGUM; BIFIDOBACTERIUM LONGUM INFANTIS; BLOATING; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; COMPETITIVE INHIBITION; CONSTIPATION; CRITICALLY ILL PATIENT; CROHN DISEASE; DIARRHEA; DIET SUPPLEMENTATION; DRUG CONTRAINDICATION; DRUG SAFETY; DRUG TOLERABILITY; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; FLATULENCE; FUNGEMIA; HUMAN; ILEITIS; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IRRITABLE COLON; LACTIC ACID BACTERIUM; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS BULGARICUS; LACTOBACILLUS CASEI; LACTOBACILLUS CRISPATUS; LACTOBACILLUS DELBRUECKII; LACTOBACILLUS FERMENTUM; LACTOBACILLUS GASSERI; LACTOBACILLUS JOHNSONII; LACTOBACILLUS PLANTARUM; LACTOBACILLUS REUTERI; LACTOBACILLUS RHAMNOSUS; MICROBIAL COLONIZATION; ORAL REHYDRATION THERAPY; PRIORITY JOURNAL; REVIEW; ROTAVIRUS; SACCHAROMYCES BOULARDII; SIDE EFFECT; STREPTOCOCCUS THERMOPHILUS; THIRST; TRAVELLER DIARRHEA; TREATMENT CONTRAINDICATION; ULCERATIVE COLITIS; VAGINA CANDIDIASIS;

EID: 77949619014     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp090168     Document Type: Review

References (76)

1. Guidelines for the evaluation of probiotics in food: report of a Joint FAO/WHO Working Group. London, Ontario, Canada: Food and Agriculture Organization of the United Nations and World Health Organization; 2002.
2. Senok AC, Ismaeel AY, Botta GA. Probiotics: facts and myths. Clin Microbiol Infect. 2005;11:958-66.
3. Schrezenmeir J, de Vrese M. Probiotics, prebiotics, and synbiotics - approaching a definition. Am J Clin Nutr. 2001; 73(suppl):361S-364S.
4. Report of a Joint FAO/WHO Expert Consultation on evaluation of health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Cordoba, Argentina: Food and Agriculture Organization of the United Nations and World Health Organization; 2001.
5. Santosa S, Farnworth E, Jones PJ. Probiotics and their potential health claims. Nutr Rev. 2006;64:265-74.
6. Alvarez-Olmos MI, Oberhelman RA. Probiotic agents and infectious diseases: a modern perspective on a traditional therapy. Clin Infect Dis. 2001;32:1567-76.
7. Doron S, Gorbach SL. Probiotics: their role in the treatment and prevention of disease. Expert Rev Anti Infect Ther. 2006; 4:261-75.
8. Pham M, Lemberg DA, Day AS. Probiotics: sorting the evidence from the myths. Med J Aust. 2008;188:304-8.
9. Vanderhoof JA, Young R. Probiotics in the United States. Clin Infect Dis. 2008; 46(suppl 2):S67-72.
10. Vanderhoof JA, Young RJ. Current and potential uses of probiotics. Ann Allergy Asthma Immunol. 2004;93(suppl 3):S33-7.
11. Goldin BR. Health benefits of probiotics. Br J Nutr. 1998;80(suppl 2):S203-7.
12. Wald A, Rakel D. Behavioral and complementary approaches for the treatment of irritable bowel syndrome. Nutr Clin Tract. 2008;23:284-92.
13. Surawicz CM. Role of probiotics in antibiotic-associated diarrhea, Clostrid ium difficile-associated diarrhea, and recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol. 2008; 42(suppl 2):S64-70.
14. MacIntyre A, Cymet TC. Probiotics: the benefits of bacterial cultures. Compr Ther. 2005;31:181-5.
15. Scarpellini E, Cazzato A, Lauritano C et al. Probiotics: which and when? Dig Dis. 2008;26:175-82.
16. Farnworth ER. The evidence to support health claims for probiotics. J Nutr. 2008; 138(suppl):1250S-4S.
17. Goldin BR, Gorbach SL. Clinical indications for probiotics: an overview. Clin Infect Dis. 2008;46(suppl 2):S96-100.
18. Reid G, Jass J, Sebulsky MT et al. Potential uses of probiotics in clinical practice. Clin Microbiol Rev. 2003;16:658-72.
19. Silva M, Jacobus NV, Deneke C et al. Antimicrobial substance from a human Lactobacillus strain. Antimicrob Agents Chemother. 1987;31:1231-3.
20. Castagliuolo I, Riegler MF, Valenick L et al. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun. 1999;67:302-7.
21. Chan RC, Reid G, Irvin RT et al. Competitive exclusion of uropathogens from human uroepithelial cells by Lactobacillus whole cells and cell wall fragments. Infect Immun. 1985;47:84-9.
22. Mack DR, Michail S, Wei S et al. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol. 1999; 276:G941-50.
23. Kaila M, Isolauri E, Soppi E et al. Enhancement of the circulating antibody secreting cell response in human diarrhea by a human Lactobacillus strain. Pediatr Res. 1992;32:141-4.
24. Probiotics. Med Lett Drugs Ther. 2007; 49:66-8.
25. Guandalini S, Pensabene L, Zikri MA et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J Pediatr Gastroenterol Nutr. 2000; 30:54-60.
26. Van Niel CW, Feudtner C, Garrison MM et al. Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis. Pediatrics. 2002;109:678-84.
27. Canani RB, Cirillo P, Terrin G et al. Probiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparations. BMJ. 2007; 335:340-2.
28. Cremonini F, Di Caro S, Nista EC et al. Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther. 2002; 16:1461-7.
29. D'Souza AL, Rajkumar C, Cooke J et al. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ. 2002;324:1361-6.
30. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol. 2006;101:812-22.
31. Klarin B, Wullt M, Palmquist I et al. Lactobacillus plantarum 299v reduces colonisation of Clostridium difficile in critically ill patients treated with antibiotics. Acta Anaesthesiol Scand. 2008;52:1096-102.
32. Dendukuri N, Costa V, McGregor M et al. Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. CMAJ. 2005;173:167-70.
33. Pillai A, Nelson RL. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev. 2008;1:CD004611.
34. Hilton E, Kolakowski P, Singer C et al. Efficacy of Lactobacillus GG as a diarrheal preventive in travelers. J Travel Med. 1997; 4:41-3.
35. Katelaris PH, Salam I, Farthing MJ. Lactobacilli to prevent traveler's diarrhea? N Engl J Med. 1995;333:1360-1. Letter.
36. McFarland LV Meta-analysis of probiotics for the prevention of traveler's diarrhea. Travel Med Infect Dis. 2007;5:97-105.
37. Wilhelm SM, Brubaker CM, Varcak EA et al. Effectiveness of probiotics in the treatment of irritable bowel syndrome. Pharmacotherapy. 2008;28:496-505.
38. McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol. 2008;14:2650-61.
39. Rembacken BJ, Snelling AM, Hawkey PM et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 1999;354:635-9.
40. Kruis W, Schutz E, Fric P et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 1997;11:853-8.
41. Kruis W, Fric P, Pokrotnieks J et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004;53:1617-23.
42. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol. 2003;15:697-8.
43. Bibiloni R, Fedorak RN, Tannock GW et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol. 2005; 100:1539-46.
44. Guslandi M, Mezzi G, Sorghi M et al. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci. 2000;45:1462-4.
45. Marteau P, Lemann M, Seksik P et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut. 2006;55:842-7.
46. Gionchetti P, Rizzello F, Venturi A et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000; 119:305-9.
47. Gionchetti P, Rizzello F, Helwig U et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology. 2003; 124:1202-9.
48. Mimura T, Rizzello F, Helwig U et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004;53:108-14.
49. Kuisma J, Mentula S, Jarvinen H et al. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther. 2003; 17:509-15.
50. Kalliomaki M, Salminen S, Arvilommi H et al. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet. 2001;357:1076-9.
51. Kalliomaki M, Salminen S, Poussa T et al. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet. 2003; 361:1869-71.
52. Isolauri E, Arvola T, Sutas Y et al. Probiotics in the management of atopic eczema. Clin Exp Allergy. 2000;30:1604-10.
53. Reid G, Bruce AW Urogenital infections in women: can probiotics help? Postgrad Med J. 2003;79:428-32.
54. Hilton E, Rindos P, Isenberg HD. Lactobacillus GG vaginal suppositories and vaginitis. J Clin Microbiol. 1995;33:1433. Letter.
55. Reid G, Bruce AW, Fraser N et al. Oral probiotics can resolve urogenital infections. FEMS Immunol Med Microbiol. 2001;30:49-52.
56. Hilton E, Isenberg HD, Alperstein P et al. Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for candidal vaginitis. Ann Intern Med. 1992; 116:353-7.
57. Kligler B, Cohrssen A. Probiotics. Am Fam Physician. 2008;78:1073-8.
58. Natural Medicines Comprehensive Database. Lactobacillus monograph. www.naturaldatabase.com (accessed 2009 Mar 23).
59. Sutton A. Product development of probiotics as biological drugs. Clin Infect Dis. 2008;46(suppl2):S128-32.
60. Kailasapathy K. Microencapsulation of probiotic bacteria: technology and potential applications. Curt Issues Intest Microbiol. 2002;3:39-48.
61. Katz JA, Pirovano F, Matteuzzi D et al. Commercially available probiotic preparations: are you getting what you pay for? Gastroenterology. 2002;122(suppl 1): A-459. Abstract.
62. Sanders ME. Probiotics: background and product table, www.usprobiotics.org (accessed 2009 Mar 23).
63. Natural Medicines Comprehensive Database. Yogurt monograph, www.natural database.com (accessed 2009 Mar 23).
64. Karpa KD. Probiotics for Clostridium difficile diarrhea: putting it into perspective. Ann Pharmacother. 2007;41:1284-7.
65. Snydman DR. The safety of probiotics. Clin Infect Dis. 2008;46(suppl 2):S104-11.
66. Borriello SP, Hammes WP, Holzapfel W et al. Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis. 2003;36:775-80.
67. Salminen MK, Rautelin H, Tynkkynen S et al. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clin Infect Dis. 2004;38:62-9.
68. Munoz P, Bouza E, Cuenca-Estrella M et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis. 2005;40:1625-34.
69. Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr. 2006;83:1256-64.
70. Salminen MK, Tynkkynen S, Rautelin H et al. Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis. 2002;35:1155-60.
71. Besselink MG, van Santvoort HC, Buskens E et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371:651-9.
72. Natural Medicines Comprehensive Database. Bifidobacteria monograph, www. naturaldatabase.com (accessed 2009 Mar 23).
73. Natural Medicines Comprehensive Database. Saccharomyces boulardii monograph, www.naturaldatabase.com (accessed 2009 Mar 23).
74. Florastor {Saccharomyces boulardii lyo) package insert. Beauvais, France: Biocodex; 2005-09.
75. Drugdex System. Lactobacillus monograph. Greenwood Village, CO: Thomson Micromedex (accessed 2009 Mar 23).
76. Drugdex System. Saccharomyces boulardii monograph. Greenwood Village, CO: Thomson Micromedex (accessed 2009 Mar 23).